189 related articles for article (PubMed ID: 30342171)
21. Bioequivalence. An updated reappraisal addressed to applications of interchangeable multi-source pharmaceutical products.
Marzo A; Balant LP
Arzneimittelforschung; 1995 Feb; 45(2):109-15. PubMed ID: 7710428
[TBL] [Abstract][Full Text] [Related]
22. Integrating systems approaches into pharmaceutical sciences.
Westerhoff HV; Mosekilde E; Noe CR; Clemensen AM
Eur J Pharm Sci; 2008 Sep; 35(1-2):1-4. PubMed ID: 18602464
[TBL] [Abstract][Full Text] [Related]
23. Harmonization of bioavailability and bioequivalence requirements.
McGilveray IJ; Ormsby E
Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():533-40. PubMed ID: 1820935
[TBL] [Abstract][Full Text] [Related]
24. Summary workshop report: Facilitating oral product development and reducing regulatory burden through novel approaches to assess bioavailability/bioequivalence.
Polli JE; Cook JA; Davit BM; Dickinson PA; Argenti D; Barbour N; García-Arieta A; Geoffroy JM; Hartauer K; Li S; Mitra A; Muller FX; Purohit V; Sanchez-Felix M; Skoug JW; Tang K
AAPS J; 2012 Sep; 14(3):627-38. PubMed ID: 22684402
[TBL] [Abstract][Full Text] [Related]
25. [What has been done for international harmonization and what remains to be solved?].
Mitsuhashi H
Gan To Kagaku Ryoho; 1997 Jan; 24(2):238-45. PubMed ID: 9030237
[TBL] [Abstract][Full Text] [Related]
26. Challenges and opportunities in establishing scientific and regulatory standards for assuring therapeutic equivalence of modified-release products: workshop summary report.
Chen ML; Shah VP; Ganes D; Midha KK; Caro J; Nambiar P; Rocci ML; Thombre AG; Abrahamsson B; Conner D; Davit B; Fackler P; Farrell C; Gupta S; Katz R; Mehta M; Preskorn SH; Sanderink G; Stavchansky S; Temple R; Wang Y; Winkle H; Yu L
Eur J Pharm Sci; 2010 May; 40(2):148-53. PubMed ID: 20347972
[TBL] [Abstract][Full Text] [Related]
27. Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products (OIPs): Workshop Summary Report.
Adams WP; Ahrens RC; Chen ML; Christopher D; Chowdhury BA; Conner DP; Dalby R; Fitzgerald K; Hendeles L; Hickey AJ; Hochhaus G; Laube BL; Lucas P; Lee SL; Lyapustina S; Li B; O'Connor D; Parikh N; Parkins DA; Peri P; Pitcairn GR; Riebe M; Roy P; Shah T; Singh GJ; Sharp SS; Suman JD; Weda M; Woodcock J; Yu L
J Aerosol Med Pulm Drug Deliv; 2010 Feb; 23(1):1-29. PubMed ID: 20131983
[TBL] [Abstract][Full Text] [Related]
28. Incorporating the patient's perspective into drug development and communication: an ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001.
Acquadro C; Berzon R; Dubois D; Leidy NK; Marquis P; Revicki D; Rothman M;
Value Health; 2003; 6(5):522-31. PubMed ID: 14627058
[TBL] [Abstract][Full Text] [Related]
29. International Conference on Harmonization: Recent Reforms as a Driver of Global Regulatory Harmonization and Innovation in Medical Products.
Lindström-Gommers L; Mullin T
Clin Pharmacol Ther; 2019 Apr; 105(4):926-931. PubMed ID: 30428144
[TBL] [Abstract][Full Text] [Related]
30. Statistical concepts in the planning and evaluation of drug safety from clinical trials in drug development: issues of international harmonization.
O'Neill RT
Stat Med; 1995 May 15-30; 14(9-10):117-27. PubMed ID: 7569506
[TBL] [Abstract][Full Text] [Related]
31. Individual bioequivalence--a European perspective.
Steinijans VW; Hauschke D
J Biopharm Stat; 1997 Mar; 7(1):31-4. PubMed ID: 9056585
[TBL] [Abstract][Full Text] [Related]
32. Workshop/conference report on EMA draft guideline on validation of bioanalytical methods.
Blume H; Brendel E; Brudny-Klöppel M; Grebe S; Lausecker B; Rohde G; Siethoff C
Eur J Pharm Sci; 2011 Feb; 42(3):300-5. PubMed ID: 21185936
[TBL] [Abstract][Full Text] [Related]
33. International harmonization of bioanalysis regulation: discussion in Global Bioanalysis Consortium harmonization teams.
Imazato M
Bioanalysis; 2013 Feb; 5(3):281-3. PubMed ID: 23394694
[TBL] [Abstract][Full Text] [Related]
34. Regulatory utility of physiologically based pharmacokinetic modeling for assessing food impact in bioequivalence studies: A workshop summary report.
Al Shoyaib A; Riedmaier AE; Kumar A; Roy P; Parrott NJ; Fang L; Tampal N; Yang Y; Jereb R; Zhao L; Wu F
CPT Pharmacometrics Syst Pharmacol; 2023 May; 12(5):610-618. PubMed ID: 36597353
[TBL] [Abstract][Full Text] [Related]
35. Bioanalysis-related highlights from the 2011 AAPS National Biotechnology Conference.
Crisino RM; Dulanto B
Bioanalysis; 2011 Aug; 3(16):1809-14. PubMed ID: 21877889
[TBL] [Abstract][Full Text] [Related]
36. Metabolites and bioequivalence: past and present.
Jackson AJ; Robbie G; Marroum P
Clin Pharmacokinet; 2004; 43(10):655-72. PubMed ID: 15244496
[TBL] [Abstract][Full Text] [Related]
37. A comparative analysis of biopharmaceutics classification system and biopharmaceutics drug disposition classification system: a cross-sectional survey with 500 bioequivalence studies.
Cristofoletti R; Chiann C; Dressman JB; Storpirtis S
J Pharm Sci; 2013 Sep; 102(9):3136-44. PubMed ID: 23580377
[TBL] [Abstract][Full Text] [Related]
38. Variability and impact on design of bioequivalence studies.
Van Peer A
Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):146-53. PubMed ID: 20041877
[TBL] [Abstract][Full Text] [Related]
39. 2010 white paper on recent issues in regulated bioanalysis & global harmonization of bioanalytical guidance.
Savoie N; Garofolo F; van Amsterdam P; Bansal S; Beaver C; Bedford P; Booth BP; Evans C; Jemal M; Lefebvre M; Lopes de Silva AL; Lowes S; Marini JC; Massé R; Mawer L; Ormsby E; Rocci ML; Viswanathan C; Wakelin-Smith J; Welink J; White JT; Woolf E
Bioanalysis; 2010 Dec; 2(12):1945-60. PubMed ID: 21110739
[TBL] [Abstract][Full Text] [Related]
40. Fighting trafficking of falsified and substandard medicinal products in Russia.
Fayzrakhmanov NF
Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
